Dr Brian Feagan and colleagues from the United Kingdom randomized a total of 778 patients with Crohn's disease to placebo or adalimumab 40 mg every other week or adalimumab 40 mg weekly, all after an 80-mg/40-mg adalimumab induction regimen.
The team compared all-cause and Crohn's disease-related hospitalizations and major Crohn's disease-related surgeries between the placebo and adalimumab groups.
The researchers found that both 3- and 12-month hospitalization risks were significantly lower for patients who received adalimumab.
Hazard ratios for all-cause hospitalization were 0.5, 0.3, and 0.4 for the adalimumab every other week, weekly, and combined groups, respectively.
The team found that hazard ratios for Crohn's disease-related hospitalization were 0.50, 0.3, and 0.4, respectively.
Cox model estimates demonstrated adalimumab every other week were associated with 52% relative reductions in 12-month all-cause hospitalization risk.
Adalimumab weekly maintenance therapies were associated with 60% relative reductions in 12-month all-cause hospitalization risk.
|Weekly adalimumab reduced Crohn's-related hospitalization risk by 60%|
The researchers found that adalimumab every other week was associated with 48% relative reductions in 12-month risk of Crohn's disease-related hospitalization.
For weekly maintenance therapies, adalimumab was associated with 60% relative reductions in 12-month Crohn’s disease-related hospitalization risk.
The combined adalimumab group was associated with 56% reductions in both all-cause, and Crohn's disease-related hospitalization risks.
Fewer Crohn's disease-related surgeries occurred in the adalimumab every other week, weekly, and combined groups compared with placebo.
Dr Feagan’s team concluded, “Patients with moderate-to-severe Crohn's disease treated with adalimumab had lower 1-year risks of hospitalization and surgery than placebo patients.”